EPO's Decision to Amend Myriad’s BRCA1 IP May Create More Uncertainty for Euro Labs

The European Patent Office’s recent decision to partly uphold Myriad Genetics’ BRCA1 patent may create uncertainty about when laboratories conducting BRCA testing in Europe infringe the IP.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.